Post Reply
4001-4020 of 10899
My trading style is way different from Livermore's.
I can't stand even a small loss,
thus I cut loss very fast.
The moment the subtle signs show that I am wrong in my anticipation, I promptly dump...
There's always another good trade to be taken... 
junction ( Date: 03-Apr-2010 11:11) Posted:
|
Thsoe who entered @ .705/.71 may wish to hold and let their profit run...
While ordering their dinner @TungLok...
hehehe...
I Punter must have made money on Biosensor. He is obviously a shrewd investor although I cannot fathom his trading technique. I can better understand Livermore's strategy. I still need to learn from both of them.
pharoah88 ( Date: 02-Apr-2010 21:23) Posted:
|
biO has nO sensOr ????
junction ( Date: 30-Mar-2010 19:22) Posted:
|
Nomura has yet come out with another report on Biosensors. ( I admire their pro-active approach and enthusiam, and the courage of their conviction).
Main points are :
. They say that there is no fundamental basis for the steep drop in price. Their RECENT plant visit shows that operations are running smoothly with 24 hr shfts, 7 days a week.
. Biosensors' distributor, Krauth continues to distribute the Bio-matrix in Germany, and will likely present clinical data in the German Cardiac meeting on 8th April.
. Key events happening for Biosensors in Q1 2011 (ie Apr 2010 - Jun 2010), Namely,
Terumo's Nobori Japan Clinical Trial update on 29th Apr 2010, during the TCT Asia Pacific meeting in Korea.
Nobori 2 trial subgroup results on may 27, during the EuroPcr meeting.
Biuosensors Q4 2010 results which will include the scorecard from the mkt in France.
From the technical perspective, The stock has dropped closed to its 200 day mva, before rebounding yesterday. There is no sign of trend reversal yet (ie the stock is in an intermediate downtrend), until we see a base building effect ( ie a saucer shape formation, or a higher high being formed) but it is a good start.
Looking at the weekly chart, a Japanese candlestick hammer has been formed, which often indicates that a bottom has been formed, and this signal will be more validated if the next candle ( ie the whole of next week) does not violate the 0.695 low.
For info. Not a call to buy/sell.
The BIG bet
Let’s look at management’s stated objectives: Increase sales, Increase profitability, Unlock shareholder value. Based on these objectives management has achieved the first 2 goals: sustainable sales growth and sustainable profit growth generated by internally created sales. What appears to show little progress is creating shareholder value as reflected in a higher share price. Normally when sales and income increase, so does the share price, but not here, as yet. Especially in view of the latest share slump with no apparent trigger. BIG’s TOTAL VALUE case has been supported by Nomura based on the current sales and earning forecasts. The share price has NOT approached this value. These forecasts, although doubted by CS, seem reasonable based on the prior nine months actual data and the new product markets that have just been opened. We will all see shortly how accurate the forecasts have been, but my feeling is that Nomura is conservative and that there will be an upside surprise. (As is normally the situation, where management is trying to build value.)
TERUMO will announce some clinical trial results shortly which, if similar to BIG’s trial results, will prove the efficacy of the BIG product and may also show it’s superiority to most larger rivals’ products. (As BIG demonstrated against J&J and thereby Boston, which is proven inferior to JNJ). This should have increase sales.
Could it be that speculators have focused on M&A as a quick way to unlock value i.e. boost share price?
BIG tried to capitalise it’s JWS partnership by purchasing the entire company but was forbidden by Chinese regulators. So how does BIG realize it’s investment? Could it, as suggested by Nomura, float JWS in China and then distribute the proceeds to shareholders? This scenario would see cash available for distribution of approximately .70 (if it realizes just the low end market estimate).
As stated by Nomura, BIG’s technology may be attractive to other interventional players but Terumo should be the natural partner as it has an extensive license agreement in place. This license may be a draw back to other players as it grants access to Terumo of BIG’s proven existing technology.
As there has been little progress on this front could speculators have become discouraged and fled?
The BIG bet is: will good clinical results, increased sales and profitability be enough to move BIG’s share price closer to its value??
Your thoughts please
Is it based on your chart reading or some news? Wonder when the blood letting will stop.
iPunter ( Date: 30-Mar-2010 17:18) Posted:
|
.705/.71 is a good entry price ...
I would like to think that a reverse head and shoulder formation is forming..with the neckline at 80cts..I'm no chartist..ha...so i dunno where is the bottom...66cts? then again who's been selling?? can someone get some transparency in this selling?
where is the chart?
it was an EightEr ?
kivine ( Date: 30-Mar-2010 00:37) Posted:
|
those who vested at .705 earlier should be very happy now.....when stock turn down, ppl will speculate the reasons for its downtrend....reasons like obama bill health......bla bla bla.....more importantly is to see if the stock is overbought or oversold....
This is a good and interesting stock... 
deliberate pushdown for pushing up later...
at the rate this is going, support will be at 0.59
serious selling man...sell Q is swelling up...maybe some insider news about medical trial issues? or simply a case of BB profit taking or shorting? it's alredy down 17% from its high.
This was reported on the 16th of march. What happrened after this for the share price to fall?
|
DJ MARKET TALK: Biosensors +0.6%; China Prospects Solid -Nomura (2010/03/16 11:43AM)
0343 GMT [Dow Jones] Biosensors (B20.SG) +0.6% at S$0.785 in active trade as investors re-look at stock after 8.2% fall since beginning March. Recent weakness triggered partly by concerns over heart stent maker''s distribution business in Germany following Medtronics'' acquisition of Invatec, affiliate Krauth Cardiovascular, which distributes Biosensors'' flagship BioMatrix stent in Germany, one of Europe''s major stent markets. Nomura says "recent share price correction presents an attractive entry level;" has Buy call with S$1.17 target. Notes, Shandong Weigao''s (8199.HK) recent positive 2H10 stent pricing guidance bodes well for Biosensors as latter has substantial presence in China; adds, Weigao management''s guidance exceeds market expectations, advises investors "to focus on the sustainable volume growth potential of 30% per annum in China''s stent market." Orderbook quotes suggest minimal upside beyond S$0.80. (frankie.ho@dowjones.com) |
Yes, it will move to that direction.
pharoah88 ( Date: 24-Mar-2010 18:21) Posted:
|
Wise information.
topdog22 ( Date: 24-Mar-2010 23:36) Posted:
|
Well, I guess we know how predictive "chartview" is!
I do not see how the US healthcare Bill could negatively impact BIG for: 1) BIG does NOT sell in the US: 2) It appears as though the bill will drive up consumption. The US has never effectively limited the amount medical drug or medical device companies have charged US people. If you look at the statistics, it is apparant the after Japan the US has the highest device and drug costs in the world.
What do you think is causing this run?
Senior seems to have a good insight
Health BiLL WiLL increase US Consumptions since peOple dO nOt have wOrry abOut Health Expenditure.
There is nO nEEd tO savE fOr Health CARE anymOre in USA.
DON'T CARE about HEALTHCARE as HEALTH BILL takes ALL CARE.
SingapOreans savE and savE and savE because they are ALL wOrred abOut HEALTHCARE as there is nO HEALTH BILL tO take CARE or ALL HEALTH CARE
Hulumas ( Date: 24-Mar-2010 15:06) Posted:
|